Brokerages Set Icon Plc (NASDAQ:ICLR) Price Target at $162.57

Shares of Icon Plc (NASDAQ:ICLR) have been assigned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $163.71.

ICLR has been the topic of several research analyst reports. KeyCorp boosted their price objective on Icon from $157.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday. BidaskClub upgraded Icon from a “hold” rating to a “buy” rating in a report on Saturday, July 27th. Mizuho boosted their price objective on Icon from $160.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Barclays restated a “hold” rating and set a $154.00 price target on shares of Icon in a report on Wednesday, April 17th. Finally, Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Friday, August 2nd.

Shares of ICLR stock traded down $0.71 on Wednesday, hitting $155.50. The stock had a trading volume of 252,547 shares, compared to its average volume of 281,123. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.07 and a quick ratio of 2.07. The firm has a market capitalization of $8.48 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 2.16 and a beta of 0.59. Icon has a 1 year low of $118.10 and a 1 year high of $165.13. The firm has a 50 day moving average of $153.43.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.01. The firm had revenue of $695.14 million for the quarter, compared to the consensus estimate of $693.56 million. Icon had a return on equity of 25.02% and a net margin of 13.05%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.51 EPS. Equities analysts forecast that Icon will post 6.87 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BB&T Securities LLC increased its holdings in Icon by 0.7% during the 2nd quarter. BB&T Securities LLC now owns 13,189 shares of the medical research company’s stock worth $2,030,000 after purchasing an additional 96 shares during the period. First Allied Advisory Services Inc. boosted its position in shares of Icon by 7.2% during the 2nd quarter. First Allied Advisory Services Inc. now owns 1,587 shares of the medical research company’s stock worth $244,000 after acquiring an additional 107 shares in the last quarter. BB&T Corp boosted its position in shares of Icon by 2.5% during the 2nd quarter. BB&T Corp now owns 4,560 shares of the medical research company’s stock worth $702,000 after acquiring an additional 110 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Icon by 2.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 5,958 shares of the medical research company’s stock worth $814,000 after acquiring an additional 131 shares in the last quarter. Finally, Greenwood Capital Associates LLC boosted its position in shares of Icon by 3.2% during the 1st quarter. Greenwood Capital Associates LLC now owns 4,981 shares of the medical research company’s stock worth $680,000 after acquiring an additional 155 shares in the last quarter. Institutional investors own 85.82% of the company’s stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading: Cryptocurrencies

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit